Table 1.
Baseline characteristics of patients between SR and NOAF group.
| Variables | SR (n = 507) | NOAF (n = 42) | P |
|---|---|---|---|
| Age (years) | 63.0 (53.0–72.0) | 69.5 (65.8–75.2) | <0.001 |
| Female (n%) | 99.0 (19.5) | 12.0 (28.6) | 0.161 |
| Hypertension (n%) | 243.0 (47.9) | 26.0 (61.9) | 0.082 |
| Diabetes mellitus (n%) | 129.0 (25.4) | 25.0 (59.5) | <0.001 |
| Killip class ≥ II | 145.0 (28.6) | 23.0 (54.8) | <0.001 |
| Smoking (n%) | 266.0 (52.5) | 20.0 (47.6) | 0.546 |
| Alcohol intake (n%) | 248.0 (48.9) | 22.0 (52.4) | 0.666 |
| Body mass index (Kg/m2) | 25.1 (24.1–26.4) | 25.5 (24.7–27.2) | 0.027 |
| Biochemical markers | |||
| Hemoglobin (g/l) | 141.0 (129.0–154.0) | 134.5 (121.8–144.3) | 0.041 |
| White blood cell (109/l) | 10.8 (8.8–12.7) | 13.2 (10.5–16.2) | <0.001 |
| Neutrophil (109/l) | 8.6 (6.7–10.7) | 11.2 (8.2–13.7) | <0.001 |
| Platelet (109/l) | 176.0 (140.0–220.0) | 151.0 (133.3–198.0) | 0.040 |
| Glucose (mmol/l) | 5.52 (4.76–6.86) | 7.87 (5.63–10.89) | <0.001 |
| Total cholesterol (mmol/l) | 4.13 (3.54–4.84) | 3.95 (3.28–4.55) | 0.111 |
| Triglyceride (mmol/l) | 1.33 (0.98–2.01) | 2.09 (1.51–2.67) | <0.001 |
| HDL-c (mmol/l) | 1.16 (1.02–1.32) | 1.26 (1.07–1.41) | 0.042 |
| LDL-c (mmol/l) | 2.36 (1.97–2.89) | 2.05 (1.72–2.55) | 0.007 |
| TyG index | 8.73 (8.33–9.19) | 9.38 (9.03–10.00) | <0.001 |
| eGFR (ml/min*1.73 m2) | 121.23 (97.46–147.87) | 95.31 (74.38–132.03) | 0.002 |
| Peak CK (*103) | 1.55 (0.87–2.85) | 1.57 (0.61–2.64) | 0.566 |
| Uric acid (μmol/l) | 353.7 (287.8–430.3) | 361.8 (305.6–428.8) | 0.644 |
| Albumin (g/l) | 36.70 ± 3.83 | 35.80 ± 4.34 | 0.149 |
| Coronary angiography | |||
| TIMI flow grade <3 pre-PCI | 395.0 (77.9%) | 36.0 (85.7%) | 0.237 |
| Stent length (mm) | 29.0 (21.0–33.0) | 29.0 (23.0–36.0) | 0.052 |
| SYNTAX score | 19.5 (14.0–23.5) | 20.0 (15.4–25.5) | 0.134 |
| Culprit vessels | 0.405 | ||
| LAD (n%) | 277.0 (54.6) | 20.0 (47.6) | |
| LCX (n%) | 39.0 (7.7) | 2.0 (4.8) | |
| RCA (n%) | 191.0 (37.7) | 20.0 (47.6) | |
| Echocardiography | |||
| Left atrium diameter (mm) | 36.0 (33.0–40.0) | 39.5 (37.0–42.0) | <0.001 |
| LVEF (%) | 51.0 (47.0–56.0) | 48.0 (44.3–55.0) | 0.012 |
| In-hospital outcomes | |||
| Hospitalization days | 12.0 (11.0–14.0) | 16.0 (11.0–18.2) | 0.001 |
| Stroke (n%) | 5.0 (1.0) | 2.0 (4.8) | 0.094 |
| Pulmonary edema (n%) | 51.0 (10.1) | 18.0 (42.9) | <0.001 |
| Cardiogenic shock (n%) | 57.0 (11.2) | 14.0 (33.3) | <0.001 |
| Death (n%) | 15.0 (3.0) | 6.0 (14.3) | 0.001 |
| Post-PCI VT (n%) | 12.0 (2.4) | 6.0 (14.3) | <0.001 |
| IABP implantation (n%) | 5.0 (1.0) | 3.0 (7.1) | 0.011 |
| Medications use at discharge | |||
| ACEI/ARB (n%) | 404.0 (79.7) | 34.0 (81.0) | 0.844 |
| Beta blockers (n%) | 362.0 (71.4) | 29.0 (69.0) | 0.746 |
| MRA (n%) | 218.0 (43.0) | 19.0 (45.2) | 0.778 |
| Statin (n%) | 499.0 (98.4) | 40.0 (95.2) | 0.378 |
SR, sinus rhythm; NOAF, new-onset atrial fibrillation; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; TyG index, Triglyceride-glucose index; eGFR, estimated glomerular filtration rate; CK, creatine kinase; TIMI, Thrombolysis In Myocardial Infarction; SYNTAX, SYNergy between Percutaneous Coronary Intervention with TAXus and cardiac surgery; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; IABP, intra-aortic ballon pump; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.